# DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

> **NCT03115333** · NA · ACTIVE_NOT_RECRUITING · sponsor: **ECOG-ACRIN Cancer Research Group** · enrollment: 146 (actual)

## Conditions studied

- Gliosarcoma
- Recurrent Glioblastoma

## Interventions

- **DIAGNOSTIC_TEST:** Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03115333
- **Lead sponsor:** ECOG-ACRIN Cancer Research Group
- **Sponsor class:** NETWORK
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-05-07
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03115333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03115333, "DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03115333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*